Mathematical modeling of the batch adsorption of proteins on new restricted access media with poly(ethylene glycol) as a semi-permeable barrier using compact finite differences

<div><p>Abstract In this work we describe a mathematical analysis of the batch adsorption process of several proteins using a new restricted access medium consisting of agarose beads grafted with poly(ethylene glycol) (PEG) as a semi-permeable barrier and immobilized metal ions or ion exchange groups as binding sites. The model was fitted to experimental data, allowing the estimation of the adsorption rate constant and the effective diffusivity for each protein. The model was solved using compact finite differences in a MATLAB® platform. According to the results, the presence of grafted PEG reduces the adsorption of all proteins to different extent; with high molecular weight proteins being affected the most. The model also establishes a reduction in the adsorption rate constant (which affects protein interaction with binding sites). The movement of the protein molecules in the adsorbent pores is also affected by the grafted PEG, but to a lesser extent.</p></div

Oxopyrido[2,3‑<i>d</i>]pyrimidines as Covalent L858R/T790M Mutant Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors

In nonsmall cell lung cancer (NSCLC), the threonine⁷⁹⁰–methionine⁷⁹⁰ (T790M) point mutation of EGFR kinase is one of the leading causes of acquired resistance to the first generation tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib. Herein, we describe the optimization of a series of 7-oxopyrido­[2,3-<i>d</i>]­pyrimidinyl-derived irreversible inhibitors of EGFR kinase. This led to the discovery of compound <b>24</b> which potently inhibits gefitinib-resistant EGFR^L858R,T790M with 100-fold selectivity over wild-type EGFR. Compound <b>24</b> displays strong antiproliferative activity against the H1975 nonsmall cell lung cancer cell line, the first line mutant HCC827 cell line, and promising antitumor activity in an EGFR^L858R,T790M driven H1975 xenograft model sparing the side effects associated with the inhibition of wild-type EGFR